Tiziana Life Sciences (TLSA)

• Market cap: $140M
• 1 day: -0.9%
• 5 days: -8.33%
• 1 month: -18.52%
• 3 months: -17.91%
• 6 months: -29.03%
• Year to date: -31.25%
• 1 year: -29.49%
• 5 years: -53.78%
• 10 years: -34.13%
• Sector: Healthcare
• Industry: Biotechnology

About: Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.

Employees: 10